Advertisement

Springer Nature is making Coronavirus research free. View research | View latest news | Sign up for updates

Economically, initiating treatment for Parkinson's disease with rasagiline dominates initiating treatment with ropinirole

    • 9 Accesses

    This is a preview of subscription content, log in to check access.

    REFERENCE

    1. 1.

      Farkouh R, Wilson MR, Tarrants ML, Castelli-Haley J, Armand C.Cost-effectiveness of rasagiline versus ropinirole extended release in delaying levodopa in the treatment of early Parkinson's disease in the United States. 13th International Congress of Parkinson's Disease and Movement Disorders: 376-377 abstr. Th-268, 7 Jun 2009. Available from: URL: http://www.movementdisorders.org

    Download references

    Rights and permissions

    Reprints and Permissions

    About this article

    Cite this article

    Economically, initiating treatment for Parkinson's disease with rasagiline dominates initiating treatment with ropinirole. Pharmacoecon. Outcomes News 581, 8 (2009). https://doi.org/10.2165/00151234-200905810-00024

    Download citation

    Keywords

    • Public Health
    • Lower Cost
    • Health Outcome
    • Levodopa
    • Markov Model